InspireMD reports Q3 EPS (17c) vs (16c) last year

Reports Q3 revenue $2.523M vs $1.81M last year. Marvin Slosman, CEO of InspireMD (NSPR), commented: “Our business demonstrated strong growth across all geographies in the third quarter of 2025. Over the last few months, our team executed our planned U.S. commercial launch of our CGuard Prime carotid stent system, which delivered measurable revenue in our initial commercial quarter in the United States. We continue to see strong demand for our solutions globally, validating our mission as we work to transform the carotid intervention market with a stent first approach.”